logo

Recursion Pharmaceuticals Inc (RXRX) Stock: A Year of Decreases and Increases

VIPS stock

Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Recursion Pharmaceuticals Inc’s current trading price is -50.07% away from its 52-week high, while its distance from the 52-week low is 68.21%. The stock’s price range during this period has varied between $4.97 and $16.75. The company, active in the Healthcare sector, saw a trading volume of around 10.17 million for the day, considerably higher average daily volume of 5.5 million observed over the last three months.

In terms of market performance, Recursion Pharmaceuticals Inc had a somewhat inconsistent run in. The highest value for the stock in the past year was $16.75 on 07/19/23, while the lowest value was $4.97 on 11/01/23.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

How Financial Performance Impacts Market Capitalization

Recursion Pharmaceuticals Inc (RXRX) has experienced a quarterly decline of -6.28% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.24B.

The Role of Moving Averages and Trading Volume in Technical Analysis

Based on Barchart.com data, the company’s moving average over the 100-day period was 9.47, with a change in price of -4.79. Similarly, Recursion Pharmaceuticals Inc recorded 6,115,844 in trading volume during the last 100 days, posting a change of -36.43%.

How RXRX’s Debt-to-Equity Ratio Affects Financial Health

A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for RXRX stands at 0.13. Similarly, the long-term debt-to-equity ratio is also 0.11.

RXRX Stock Stochastic Average

As of today, the raw stochastic average of Recursion Pharmaceuticals Inc over the last 50 days is at 41.12%. This shows a declinee from the raw stochastic average of the previous 20 days, which was recorded at 49.69%. Further, the company’s Stochastic %K and %D values for the last 20 days were 31.07% and 23.80%, respectively.

RXRX Stock Price Performance Analysis

The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. Until today this year the stock’s price performance recorded a decrease of -15.21%. However, over the last six months, the performance has been stronger by -33.07%. The price of RXRX decreased -2.56% over the last 30 days. And in the last five days, it has surged by 14.21%.

Most Popular